Potential for proteasome inhibition in the treatment of cancer

Drug Discovery Today

Volumn 8, Issue 7, 2003, Pages 307-315

  Adams, Julian ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALDEHYDE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CEP 1612; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LACTACYSTIN; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL ASSAY; DRUG ACTIVITY; DRUG DOSE REGIMEN; ENZYME INHIBITION; NONHUMAN; REVIEW; TOXICITY; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 0037376230     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02647-3     Document Type: Review

References (72)

1. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8:2001;739-758.
2. Stock D., et al. Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography. Cold Spring Harb. Symp. Quant. Biol. 60:1995;525-532.
3. Desai S.D., et al. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 272:1997;24159-24164.
4. Ogiso Y., et al. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60:2000;2429-2434.
5. Frankel A., et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6:2000;3719-3728.
6. Masdehors P., et al. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma. 38:2000;499-504.
7. Pagano M., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
8. Chiarle R., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 95:2000;619-626.
9. Waltregny D., et al. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol. Endocrinol. 15:2001;765-782.
10. Cusack J.C. Jr, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:2001;3535-3540.
11. An B., et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5:1998;1062-1075.
12. Winston J.T., et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13:1999;270-283.
13. Spencer E., et al. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 13:1999;284-294.
14. Alkalay I., et al. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10599-10603.
15. Chauhan D., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 87:1996;1104-1112.
16. Mitsiades N., et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 99:2002;4079-4086.
17. Wang C.Y., et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19:1999;5923-5929.
18. Chen C., et al. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20:2000;2687-2695.
19. Cusack J.C., et al. NF-kappaB and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappaB. Drug Resist. Updates. 2:1999;271-273.
20. Duffey D.C., et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 59:1999;3468-3474.
21. Berenson J.R., et al. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. 28:2001;626-633.
22. Wang C.Y., et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5:1999;412-417.
23. Adams J., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8:1998;333-338.
24. Orlowski R.Z., et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58:1998;4342-4348.
25. Pajonk F., et al. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;1025-1032.
26. Arlt A., et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 20:2001;859-868.
27. Desai S.D., et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61:2001;5926-5932.
28. Lauricella M., et al. Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells. Tumour Biol. 21:2000;337-348.
29. Golab J., et al. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res. 20:2000;1717-1721.
30. Sun J., et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 61:2001;1280-1284.
31. Delic J., et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Cancer. 77:1998;1103-1107.
32. Zhang L., et al. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke. 32:2001;2926-2931.
33. Phillips J.B., et al. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke. 31:2000;1686-1693.
34. Shah I.M., et al. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54:2002;269-276.
35. Adams J., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622.
36. Teicher B.A., et al. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5:1999;2638-2645.
37. Sunwoo J.B., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:2001;1419-1428.
38. Pervan M., et al. Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. 24:2001;481-485.
39. Russo S.M., et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kB. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;183-193.
40. Pink, M. et al. (2002) PS-341 enhances chemotherapeutic effect in human xenograft models, Proc. Am. Assoc. Cancer Res. 43, 158 (Abstract).
41. Gumerlock P.H., et al. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC). Clin. Cancer Res. 7:2001;157.
42. Hideshima T., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076.
43. Steiner, P. et al. (2001) Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 98, 310a (Abstract).
44. LeBlanc R., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:2002;4996-5000.
45. Aghajanian C., et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8:2002;2505-2511.
46. Orlowski R.Z., et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade™) in combination with pegylated liposomal doxorubicin (Doxil®) in patients with refractory hematologic malignancies. Blood. 100:2002;105a.
47. Ryan, D.P. et al. (2002) Pharmacokinetic and pharmacodynamic Phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.38th Annual Meeting 21, 95a.
48. Clark, J.W. et al. (2002) Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting 21, 93a.
49. Logothetis, C.J. et al. (2001) Dose-dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc. Am. Soc. Clin. Oncol. 37th Annual Meeting 20, 186a.
50. Papandreou, C.N. et al. (2000) Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 36th Annual Meeting 19, 190a.
51. Hamilton, A.L. et al. (2001) PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc. Am. Soc. Clin. Oncol. 37th Annual Meeting 20, 85a.
52. Richardson, P.G. et al. (2002) Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/refractory disease: results from cohort 1 analysis. Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting 21, 11a.
53. Stinchcombe T.E., et al. PS-341 is active in multiple myeloma: Preliminary report of a Phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood. 96:2000;516a.
54. Richardson P., et al. A Phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™ formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood. 100:2002;104a.
55. Mao Y., et al. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 276:2001;40652-40658.
56. Yang Y., et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 288:2000;874-877.
57. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3850-3855.
58. Chadebech P., et al. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. 262:1999;823-827.
59. Zhao J., et al. Pyk2 and FAK differentially regulate progression of the cell cycle. J. Cell Sci. 113:2000;3063-3072.
60. Tatebe H., Yanagida M. Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Curr. Biol. 10:2000;1329-1338.
61. Clurman B.E., et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10:1996;1979-1990.
62. Cayrol C., Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene. 17:1998;2437-2444.
63. Segnitz B., Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. 272:1997;18694-18701.
64. Nesbit C.E., et al. MYC oncogenes and human neoplastic disease. Oncogene. 18:1999;3004-3016.
65. Bounpheng M.A., et al. Degradation of Id proteins by the ubiquitin-proteasome pathway. FASEB J. 13:1999;2257-2264.
66. Palombella V.J., et al. The ubiquitin-proteasome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B. Cell. 78:1994;773-785.
67. Maki C.G., et al. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56:1996;2649-2654.
68. Boyer S.N., et al. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
69. Bold R.J., et al. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100:2001;11-17.
70. Pham L., et al. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood. 98:2001;465a. Abstract.
71. Shah S.A., et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82:2001;110-122.
72. Tan C., Waldmann T.A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T- cell leukemia. Cancer Res. 62:2002;1083-1086.